Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Standard BioTools Inc. Common Stock

LAB

Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.

Last trade $0.6133
Day change -$0.0077 (-1.24%)
Day range $0.586 – $0.625
Volume 515,884
Market cap $245M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$244.77M
Price / earnings
1.84×
Price / book
0.44×
Price / sales
2.9×
EV / sales
-0.27×
EV / EBITDA
0.53×

Profitability

Earnings per share
$0.34
Return on assets
20.95%
Return on equity
23.95%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
9.75×
Quick ratio
9.4×
Cash ratio
5.24×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$65.65M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for LAB, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$19.39M$20.1M$21.15M$23.8M$19.55M$21.76M$20.22M$24.78M
Cost of revenue$8.56M$9.57M$9.84M$12.41M$10.07M$11.13M$9.17M$13.42M
Gross profit$10.83M$10.54M$11.31M$11.38M$9.48M$10.63M$11.05M$11.36M
Selling, general and administrative$16.84M$16.39M$18.61M$25.34M$26.6M$28.11M$29.82M$27.32M
Research and development$2.08M$1.98M$2.12M$7.97M$6.36M$6.22M$5.44M$7.04M
Total operating expenses$30.6M$35.92M$23.8M$36.03M$42.42M$36.33M$38.02M$37.44M
Operating income-$19.77M-$25.39M-$12.5M-$24.64M-$32.94M-$25.7M-$26.97M-$26.08M
Interest expense$0$0$0-$5K$0$0$0-$572K
Income before taxes-$14.95M-$21.44M-$14.62M-$22.03M-$32.9M-$18.28M-$23.49M-$26.9M
Income taxes$27K$90K$11K-$35.93M-$1.22M-$609K-$119K$272K
Net income$13.48M-$26.76M$127.07M$19.28M-$34.69M-$33.46M-$26.03M-$34.07M
Net income attributable to common shareholders$13.48M-$26.76M$127.07M$19.28M-$34.69M-$33.46M-$26.03M-$34.07M
EBITDA-$6.89M-$6.56M-$8.01M-$20.63M-$21.95M-$19.71M-$20.04M-$19.05M
Basic earnings per share$0.03-$0.07$0.33$0.05-$0.09-$0.09-$0.07-$0.09
Diluted earnings per share$0.03-$0.07$0.33$0.05-$0.09-$0.09-$0.07-$0.09

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger—IRDM, VRME, VAL and LAB

Monteverde & Associates PC is investigating four merger transactions to determine if shareholders are receiving fair value. The investigations cover Iridium Communications' sale to Rocket Lab, VerifyMe's merger with Open World Ltd, Valaris' sale to Transocean Ltd, and Standard Biotools' merger with Treeline Biosciences. The firm is offering free consultations to shareholders with concerns about these deals.

GlobeNewswire Inc.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AstroNova, Inc. (Nasdaq – ALOT), Open Lending Corporation (Nasdaq – LPRO), Huntsman Corporation (NYSE – HUN), Standard BioTools Inc. (Nasdaq – LAB)

Brodsky & Smith law firm is investigating four merger transactions to determine whether company boards breached fiduciary duties to shareholders. The investigations concern AstroNova (being acquired by Arcline for $29.00/share), Open Lending (being acquired by ANV Group for $3.15/share), Huntsman (merging with Olin in a stock exchange), and Standard BioTools (being acquired by Treeline Biosciences). The firm is seeking shareholders to discuss whether fair processes were conducted and fair value provided.

Benzinga

Standard BioTools and Treeline Biosciences Announce Merger Agreement

Standard BioTools (NASDAQ:LAB) and Treeline Biosciences announced a definitive merger agreement to combine in an all-stock transaction. The combined company will operate as Treeline Biosciences under ticker 'TRLN' and will be led by Treeline CEO Josh Bilenker. The merger is expected to close in the second half of 2026, with the combined entity having over $900 million in cash runway into 2029. Standard BioTools stockholders will own approximately 16% of the combined company, while Treeline stockholders will own approximately 84%. Standard BioTools will divest its Mass Cytometry and Microfluidics businesses to maximize shareholder value.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.